Galectin Therapeutics Inc.
GALT
$3.31
-$0.22-6.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.25% | 8.91% | -10.14% | -14.56% | -8.09% |
| Total Depreciation and Amortization | -38.89% | -11.43% | 280.00% | 12.12% | 12.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.57% | -23.79% | -39.37% | -12.71% | 25.03% |
| Change in Net Operating Assets | -69.30% | -79.39% | 75.02% | -51.18% | 165.79% |
| Cash from Operations | 9.07% | -8.67% | -8.97% | -26.70% | 5.14% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -72.50% | -30.00% | -33.33% | 0.00% | 33.33% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 987.50% | -73.17% | -87.77% | -87.77% | -96.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -62.63% | -41.12% | -46.98% | -22.00% | 0.86% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -331.93% | -254.97% | -380.13% | -249.12% | 47.83% |